Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Ariotti

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Clinical Medicine Insights. Cardiology|April 29, 2021
Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case ReportAlessandro Lupi, Sara Ariotti, Doranna De Pace, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 7, 2015
Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy durationFrancesco Costa, Marianna Adamo, Sara Ariotti, et al.
American Heart Journal|March 21, 2016
Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trialGiuseppe Gargiulo, Francesco Costa, Sara Ariotti, et al.
JACC. Cardiovascular Interventions|August 20, 2016
Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM TrialMarianna Adamo, Sara Ariotti, Francesco Costa, et al.
Annals of Internal Medicine|June 13, 2017
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary InterventionRaffaele Piccolo, Giuseppe Gargiulo, Anna Franzone, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 16, 2017
Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trialGiuseppe Gargiulo, Andrea Santucci, Raffaele Piccolo, et al.
Toxicon : Official Journal of the International Society on Toxinology|September 20, 2024
Venom-induced myocarditis: An unusual case attributable to Vipera aspis biteStefano Maffè, Paola Paffoni, Emanuela Facchini, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|January 4, 2017
Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trialRaffaele Piccolo, Giulia Magnani, Sara Ariotti, et al.
JACC. Cardiovascular Interventions|August 22, 2016
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY TrialGiuseppe Gargiulo, Sara Ariotti, Andrea Santucci, et al.
JAMA Cardiology|August 31, 2016
Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical TrialAnna Franzone, Raffaele Piccolo, Giuseppe Gargiulo, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Clinical Medicine Insights. Cardiology|April 29, 2021
Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case ReportAlessandro Lupi, Sara Ariotti, Doranna De Pace, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 7, 2015
Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy durationFrancesco Costa, Marianna Adamo, Sara Ariotti, et al.
American Heart Journal|March 21, 2016
Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trialGiuseppe Gargiulo, Francesco Costa, Sara Ariotti, et al.
JACC. Cardiovascular Interventions|August 20, 2016
Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM TrialMarianna Adamo, Sara Ariotti, Francesco Costa, et al.
Annals of Internal Medicine|June 13, 2017
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary InterventionRaffaele Piccolo, Giuseppe Gargiulo, Anna Franzone, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 16, 2017
Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trialGiuseppe Gargiulo, Andrea Santucci, Raffaele Piccolo, et al.
Toxicon : Official Journal of the International Society on Toxinology|September 20, 2024
Venom-induced myocarditis: An unusual case attributable to Vipera aspis biteStefano Maffè, Paola Paffoni, Emanuela Facchini, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|January 4, 2017
Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trialRaffaele Piccolo, Giulia Magnani, Sara Ariotti, et al.
JACC. Cardiovascular Interventions|August 22, 2016
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY TrialGiuseppe Gargiulo, Sara Ariotti, Andrea Santucci, et al.
JAMA Cardiology|August 31, 2016
Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical TrialAnna Franzone, Raffaele Piccolo, Giuseppe Gargiulo, et al.
Pageof 3